• Cephalon’s (CEPH) lestaurtinib (CEP-701), an FLT3/JAK2 inhibitor, failed a late stage trial in patients with relapsed acute myelogenous leukemia (AML). Unfortunately, the drug showed no increased benefit in overall survival rate vs. patients on chemotherapy alone. [Cephalon]

• FDA going after Abbott’s (ABT) Depakote. [The Guardian]

• $15M for I-Therapeutix’ ocular hydrogel bandage. [Xconomy]

• Synta Pharmaceuticals’ (SNTA) CMO hits the road. [BizJournals]

• Seroquel doc will testify. [Bloomberg]

• American Idol Ruben Studdard at Novartis-sponsored (NVS) event in NYC!!! [PRNewswire]

• Wyeth (WYE) came cheap. [BNET Pharma]

• Finally, we end with some good news. The FDA has granted the Medicines Company (MDCO) pediatric exclusivity for Angiomax (bivalirudin) in pediatric patients aged birth to 16-years old. Thumbs up for the kiddos! [Pharmalive]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts